Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy
The study investigates the predictive value of insertion/deletion rate in gastric cancer patients treated with nivolumab plus chemotherapy.
Understanding predictive biomarkers can guide treatment decisions and improve outcomes in gastric cancer patients receiving immunotherapy and chemotherapy.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers
- Current Treatment and Recent Progress in Gastric Cancer